Are you dealing with multiple myeloma that keeps coming back or hasn't improved? If you are, you may be able to join a study to see if a new drug called ABBV-383 could be safe and helpful for people in your situation. You will be reimbursed for travel expenses. You will not have to pay for the drug while you take part in this study.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Do you have multiple myeloma with MGRS-associated kidney disease? If so, you may be able to take part in a research study looking at the safety and effectiveness of a combination of medications for patients with multiple myeloma with MGRS-associated kidney disease.

The purpose of this study is to understand what factors encourage and discourage rural and racially and ethnically diverse populations to participate in cancer clinical research studies. The study is focused on people living in Bertie, Hertford, Robseon and Scotland Co, NC and neighboring counties. We also want to hear what healthcare providers in these NC areas think about cancer clinical research barriers and facilitators.

We are doing this study to test a behavioral lifestyle program designed specifically for adolescent and young adult cancer survivors. Study participants will use a smartphone app and Fitbit activity tracker to help them develop healthier habits.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.

Do you have asymptomatic multiple myeloma, also known as smoldering multiple myeloma? You may be able to take part in a research study to help us learn more about the effectiveness of a drug called daratumumab in combination with lenalidomide and steroids.